These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25119744)

  • 1. Respiratory infections in children up to two years of age on prophylaxis with palivizumab.
    Monteiro AI; Bellei NC; Sousa AR; dos Santos AM; Weckx LY
    Rev Paul Pediatr; 2014 Jun; 32(2):152-8. PubMed ID: 25119744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab compliance in congenital heart disease patients: factors related to compliance and altered lower respiratory tract infection viruses after palivizumab prophylaxis.
    Sel K; Aypar E; Dönmez YN; Aliyev E; Aykan HH; Karagöz T; Alehan D
    Cardiol Young; 2020 Jun; 30(6):818-821. PubMed ID: 32425145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely.
    Prais D; Kaplan E; Klinger G; Mussaffi H; Mei-Zahav M; Bar-Yishay E; Stafler P; Steuer G; Sirota L; Blau H
    Chest; 2016 Mar; 149(3):801-8. PubMed ID: 26226546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates.
    Gortner L
    Klin Padiatr; 2017 Sep; 229(5):259-260. PubMed ID: 28926860
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe outcomes associated with respiratory viruses in newborns and infants: a prospective viral surveillance study in Jordan.
    Khuri-Bulos N; Lawrence L; Piya B; Wang L; Fonnesbeck C; Faouri S; Shehabi A; Vermund SH; Williams JV; Halasa NB
    BMJ Open; 2018 May; 8(5):e021898. PubMed ID: 29780032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007743. PubMed ID: 27439110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America.
    Castillo LM; Bugarin G; Arias JC; Barajas Rangel JI; Serra ME; Vain N
    J Pediatr (Rio J); 2017; 93(5):467-474. PubMed ID: 28236418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
    Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC
    Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B; Egger B; Kurath-Koller S; Urlesberger B
    Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab.
    Faldella G; Alessandroni R; Aquilano G; Vandini S; Lanari M; Silvestri M; Pistorio A; Rossi GA
    J Chemother; 2010 Feb; 22(1):30-5. PubMed ID: 20227990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab.
    Boivin G; Caouette G; Frenette L; Carbonneau J; Ouakki M; De Serres G
    J Clin Virol; 2008 May; 42(1):52-7. PubMed ID: 18164233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
    Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study.
    Chiu SN; Wang JN; Fu YC; Chung HT; Chang LY; Wu MH; Hua YC; Lin MT; Lu CW; Chen CA; Wu JM; Wang JK
    J Pediatr; 2018 Apr; 195():108-114.e1. PubMed ID: 29395174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
    Paes B; Saleem M; Kim D; Lanctôt KL; Mitchell I
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
    Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study.
    Ozyurt A; Narin N; Baykan A; Argun M; Pamukcu O; Zararsiz G; Sunkak S; Uzum K
    Pediatr Pulmonol; 2015 Oct; 50(10):1025-32. PubMed ID: 25156973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.
    Paes B; Kim D; Saleem M; Wong S; Mitchell I; Lanctot KL;
    Eur J Pediatr; 2019 Mar; 178(3):377-385. PubMed ID: 30610419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.